Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2009

View Archived Issues

Recent Georgia Tech patent describes novel HDAC inhibitors

New MAPKAP-K2 (MK2) inhibitors reported in recent Novartis patent

Combination of YM-155, docetaxel and prednisone used in prostate cancer therapy

BIBF-1120 and BIBW-2992 may be used in combination in prostate cancer treatment

Bayer discloses prodrugs of apixaban for thromboembolic disorders

Merck & Co. discloses novel orexin receptor antagonists for insomnia

New HCV NS3/NS4 protease inhibitors reported in recent Gilead patent

PharmaMar licenses kahalalide F analogues to Marinomed

Catalyst halts enrollment into phase II trial of CPP-109 for methamphetamine addiction

MMI presents update on clinical development of GVX-3322 and ONCO-4417

2008 highlights at Elan

Anacor reports encouraging results from phase I AN-2718 trial

Pharmexa and Affitech enter into conditional merger agreement

MDV-3100 displays safety and antitumor activity in phase I/II trial for prostate cancer

Vertex to acquire ViroChem and its preclinical-stage polymerase inhibitors

FDA gives positive review of InNexus' IND plans for DXL-625 in NHL and CLL

Dronedarone reduces risk of hospitalization from cardiovascular events in atrial fibrillation

Meropenem/clavulanate combination inhibits extensively drug-resistant tuberculosis

Ferring launches degarelix for advanced prostate cancer

Quest presents positive results for its photosensitizer SL-052

4SC initiates phase IIa trial for 4SC-101 in Crohn's disease

Access announces results from a phase II ovarian cancer trial of ProLindac

CV Therapeutics reports phase I proof-of-concept data for CVT-3619

GlaxoSmithKline submits MAA for pazopanib in advanced kidney cancer

NICE refuses funding for advanced breast cancer treatment, Tyverb

Proteon initiates phase I/II PRT-201 study in hemodialysis patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...